1. Managing gBRCA-Positive Metastatic Breast Cancer

3. Introduction

4. When Would You Initiate BRCA Mutation Testing?

5. BRCA Mutation Prevalence: Higher Risk Groups Appropriate for BRCA Testing

6. Prevalence of Germline BRCA1/2 Mutations

7. BRCA1/2 Testing Current Guidelines

8. Issues in BRCA Mutation Testing: When and Why?

9. Issues in BRCA Mutation Testing: When and Why? (cont)

10. Case Discussion: A Patient With BRCA+ MBC Who Did Not Receive Prior Chemotherapy

11. Clinical Case - Ms S.

12. Clinical Case - Ms S. (cont)

13. Clinical Case - Ms S. (cont)

14. Case Discussion

15. Phase 3 OlympiAD Trial: PFS

16. Phase 3 EMBRACA Study: PFS

17. OlympiAD Overall Survival and Subgroup Analysis

18. Phase 3 PARP Inhibitor Trials: Safety and QoL

19. Olaparib and Talazoparib Safety Data: AEs of Any Grade

20. Olaparib and Talazoparib QoL

21. What Is the Role of Platinum in the Treatment of BRCA1/2 Carriers?

22. Is There a Role for PARP Inhibitors in Patients With Somatic BRCA Mutations?

23. What Is the Role of PARP Inhibitors in the Adjuvant Setting?

24. Talazoparib Neoadjuvant

25. Concluding Remarks

26. Abbreviations

27. Abbreviations (cont)